Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Autor: Guijosa A; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Freyria A; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Espinosa-Fernandez JR; Department of Medical Oncology - Breast Tumors, Instituto Nacional de Cancerología, Mexico City, Mexico., Estrada-Mena FJ; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Armenta-Quiroga AS; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Ortega-Treviño MF; School of Medicine, Universidad Panamericana, Mexico City, Mexico., Catalán R; School of Medicine, Universidad Panamericana, Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, Mexico., Antonio-Aguirre B; Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, USA., Villarreal-Garza C; Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Nuevo León, Mexico., Perez-Ortiz AC; School of Medicine, Universidad Panamericana, Mexico City, Mexico.; Transplant Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Clinical and translational science [Clin Transl Sci] 2022 Oct; Vol. 15 (10), pp. 2403-2436. Date of Electronic Publication: 2022 Aug 17.
DOI: 10.1111/cts.13370
Abstrakt: Taxane-based chemotherapy regimens are used as first-line treatment for breast cancer. Neurotoxicity, mainly taxane-induced peripheral neuropathy (TIPN), remains the most important dose-limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the association remain unclear. For this reason, we systematically reviewed observational studies of TIPN pharmacogenetic markers in breast cancer treatment. We conducted a systematic search of terms alluding to breast cancer, genetic markers, taxanes, and neurotoxicity in Ovid, ProQuest, PubMed, Scopus, Virtual Health, and Web of Science. We assessed the quality of evidence and bias profile. We extracted relevant variables and effect measures. Whenever possible, we performed random-effects gene meta-analyses and examined interstudy heterogeneity with meta-regression models and subgroup analyses. This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidance. A total of 42 studies with 19,431 participants were included. These evaluated 262 single-nucleotide polymorphisms (SNPs) across 121 genes. We conducted meta-analyses on 23 genes with 60 SNPs (19 studies and 6246 participants). Thirteen individual SNPs (ABCB1-rs2032582, ABCB1-rs3213619, BCL6/-rs1903216, /CAND1-rs17781082, CYP1B1-rs1056836, CYP2C8-rs10509681, CYP2C8-rs11572080, EPHA5-rs7349683, EPHA6-rs301927, FZD3-rs7001034, GSTP1-rs1138272, TUBB2A-rs9501929, and XKR4-rs4737264) and the overall SNPs' effect in four genes (CYP3A4, EphA5, GSTP1, and SLCO1B1) were statistically significantly associated with TIPN through meta-analysis. In conclusion, through systematic review and meta-analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making.
(© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje